Lifecore Biomedical (NASDAQ:LFCR) Trading 3.8% Higher - Time to Buy?

Lifecore Biomedical, Inc. (NASDAQ:LFCR - Get Free Report)'s stock price traded up 3.8% on Thursday . The stock traded as high as $5.96 and last traded at $5.94. 97,498 shares changed hands during trading, a decline of 60% from the average session volume of 242,917 shares. The stock had previously closed at $5.72.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. Stephens restated an "equal weight" rating and set a $6.00 price objective on shares of Lifecore Biomedical in a research note on Friday, January 3rd. Craig Hallum raised their price objective on Lifecore Biomedical from $8.00 to $10.00 and gave the company a "buy" rating in a research note on Friday, November 22nd.

Lifecore Biomedical Stock Up 2.5 %

The company has a market capitalization of $225.51 million, a P/E ratio of -10.88 and a beta of 0.96. The company has a debt-to-equity ratio of 9.21, a quick ratio of 1.21 and a current ratio of 2.32. The stock has a 50 day moving average price of $6.60 and a 200 day moving average price of $5.98.

Lifecore Biomedical (NASDAQ:LFCR - Get Free Report) last released its earnings results on Thursday, January 2nd. The company reported ($0.25) EPS for the quarter, topping analysts' consensus estimates of ($0.27) by $0.02. Lifecore Biomedical had a negative return on equity of 315.23% and a negative net margin of 12.52%. Equities research analysts forecast that Lifecore Biomedical, Inc. will post -0.91 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO Paul Josephs acquired 17,000 shares of the firm's stock in a transaction that occurred on Wednesday, January 8th. The stock was bought at an average price of $5.74 per share, with a total value of $97,580.00. Following the acquisition, the chief executive officer now owns 559,717 shares in the company, valued at $3,212,775.58. The trade was a 3.13 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. 28.21% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of LFCR. Bridgeway Capital Management LLC lifted its position in Lifecore Biomedical by 2.5% in the 4th quarter. Bridgeway Capital Management LLC now owns 78,800 shares of the company's stock worth $585,000 after buying an additional 1,900 shares during the last quarter. Wells Fargo & Company MN raised its position in shares of Lifecore Biomedical by 29.0% in the 4th quarter. Wells Fargo & Company MN now owns 13,381 shares of the company's stock worth $99,000 after acquiring an additional 3,012 shares in the last quarter. Barclays PLC lifted its position in Lifecore Biomedical by 13.5% during the fourth quarter. Barclays PLC now owns 33,972 shares of the company's stock valued at $253,000 after buying an additional 4,028 shares during the period. Bank of America Corp DE boosted its stake in Lifecore Biomedical by 25.3% during the fourth quarter. Bank of America Corp DE now owns 33,507 shares of the company's stock worth $249,000 after acquiring an additional 6,776 shares in the last quarter. Finally, ARS Investment Partners LLC bought a new stake in shares of Lifecore Biomedical in the 4th quarter worth approximately $74,000. Hedge funds and other institutional investors own 83.36% of the company's stock.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.